South Korea Orders Sanofi-Aventis To Recall Contaminated Heparin
This article was originally published in PharmAsia News
Executive Summary
TOKYO - South Korea's food and drug protection agency announced it has ordered the local unit of French drug maker Sanofi-Aventis SA to recall its top-selling heparin drug after finding an unspecified amount of impure material in the product
You may also be interested in...
U.S. FDA Pinpoints Culprit In Bad Heparin
U.S. FDA has evaluated data that provides "a very solid mechanistic link" between patients who have received bolus dosing of contaminated heparin and observed adverse reactions, according to Center for Drug Evaluation and Research Director Janet Woodcock
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).